Françoise Morin
Françoise Morin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Planel
Faculty of Medicine, Department of Psychiatry and Neurosciences, CR‐CHUQ Laval University Québec City Quebec Canada
2 shared publications - Geoffrey Canet
IGF, University of Montpellier, CNRS, INSERM
2 shared publications - Luc Vallières
Centre de Recherche du CHU de Québec - Université Laval, Axe Neurosciences, Québec, Canada
2 shared publications Alexandre Patenaude
Neuroscience Unit, University Hospital Center of Quebec, Laval University, Quebec City, Quebec, Canada
1 shared publication- Aline Dumas
Neuroscience Unit, University Hospital Center of Quebec, Laval University, Quebec City, Quebec, Canada
1 shared publication - Anna Park
Large Molecule Research
1 shared publication
Latest Publications
- Open Access
- 17 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (51)
Turncoat antibodies unmasked in a model of autoimmune demyelination: From biology to therapy
Autoantibodies contribute to many autoimmune diseases, yet there is no approved therapy to neutralize them selectively. A popular mouse model, experimental autoimmune encephalomyelitis (EAE), could serve to develop such a therapy, provided we can better understand the nature and importance of the autoantibodies involved. Here, we report the finding of autoantibody-secreting extrafollicular plasmablasts in EAE induced with specific myelin oligodendrocyte glycoprotein (MOG) antigens. Single-cell RNA sequencing reveals that these cells produce nonaffinity-matured IgG antibodies. These include pathogenic antibodies competing for shared binding space on MOG’s extracellular domain. Interestingly, the synthetic anti-MOG antibody 8-18C5 can prevent the binding of pathogenic antibodies from either EAE mice or people with MOG antibody disease. Moreover, an 8-18C5 variant carrying the NNAS mutation, which inactivates its effector functions, can reduce EAE severity and promote functional recovery. In brief, this study provides not only a comprehensive characterization of the humoral response in EAE models but also a proof of concept for a therapy to antagonize pathogenic anti-MOG antibodies.
- 17 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (51)
Open AccessTurncoat antibodies unmasked in a model of autoimmune demyelination: From biology to therapy
Autoantibodies contribute to many autoimmune diseases, yet there is no approved therapy to neutralize them selectively. A popular mouse model, experimental autoimmune encephalomyelitis (EAE), could serve to develop such a therapy, provided we can better understand the nature and importance of the autoantibodies involved. Here, we report the finding of autoantibody-secreting extrafollicular plasmablasts in EAE induced with specific myelin oligodendrocyte glycoprotein (MOG) antigens. Single-cell RNA sequencing reveals that these cells produce nonaffinity-matured IgG antibodies. These include pathogenic antibodies competing for shared binding space on MOG’s extracellular domain. Interestingly, the synthetic anti-MOG antibody 8-18C5 can prevent the binding of pathogenic antibodies from either EAE mice or people with MOG antibody disease. Moreover, an 8-18C5 variant carrying the NNAS mutation, which inactivates its effector functions, can reduce EAE severity and promote functional recovery. In brief, this study provides not only a comprehensive characterization of the humoral response in EAE models but also a proof of concept for a therapy to antagonize pathogenic anti-MOG antibodies.
- 31 January 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (9) , 1930-1956
Advancing Alzheimer's disease pharmacotherapy: efficacy of glucocorticoid modulation with dazucorilant (CORT113176) in preclinical mouse models
Background and Purpose: Exposure to chronic stress and high levels of glucocorticoid hormones in adulthood has been associated with cognitive deficits and increased risk of Alzheimer's disease (AD). Dazucorilant has recently emerged as a selective glucocorticoid receptor (NR3C1) modulator, exhibiting efficacy in counteracting amyloid‐β toxicity in an acute model of AD. We aim to assess the therapeutic potential of dazucorilant in reversing amyloid and tau pathologies through the inhibition of glucocorticoid receptor pathological activity, and providing additional evidence for its consideration in AD treatment.Experimental Approach: The efficacy of dazucorilant was evaluated in two transgenic mouse models of amyloid pathology. The slowly progressing J20 and the aggressively pathological 5xFAD mice. Behavioural analysis was conducted to evaluate welfare, cognitive performances and anxiety levels. The activity of the glucocorticoid receptor system, neuroinflammation, amyloid burden and tau phosphorylation were examined in hippocampi.Key Results: In both AD models, chronic treatment with dazucorilant improved working and long‐term spatial memories along with the inhibition of glucocorticoid receptor‐dependent pathogenic processes and the normalization of plasma glucocorticoid levels. Dazucorilant treatment also resulted in a reduction in tau hyperphosphorylation and amyloid production and aggregation. Additionally, dazucorilant seemed to mediate a specific re‐localization of activated glial cells onto amyloid plaques in J20 mice, suggesting a restoration of physiological neuroinflammatory processes.Conclusion and Implications: Dazucorilant exhibited sustained disease‐modifying effects in two AD models. Given that this compound has demonstrated safety and tolerability in human subjects, our results provide pre‐clinical support for conducting clinical trials to evaluate its potential in AD.
- 31 January 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (9) , 1930-1956
Advancing Alzheimer's disease pharmacotherapy: efficacy of glucocorticoid modulation with dazucorilant (CORT113176) in preclinical mouse models
Background and Purpose: Exposure to chronic stress and high levels of glucocorticoid hormones in adulthood has been associated with cognitive deficits and increased risk of Alzheimer's disease (AD). Dazucorilant has recently emerged as a selective glucocorticoid receptor (NR3C1) modulator, exhibiting efficacy in counteracting amyloid‐β toxicity in an acute model of AD. We aim to assess the therapeutic potential of dazucorilant in reversing amyloid and tau pathologies through the inhibition of glucocorticoid receptor pathological activity, and providing additional evidence for its consideration in AD treatment.Experimental Approach: The efficacy of dazucorilant was evaluated in two transgenic mouse models of amyloid pathology. The slowly progressing J20 and the aggressively pathological 5xFAD mice. Behavioural analysis was conducted to evaluate welfare, cognitive performances and anxiety levels. The activity of the glucocorticoid receptor system, neuroinflammation, amyloid burden and tau phosphorylation were examined in hippocampi.Key Results: In both AD models, chronic treatment with dazucorilant improved working and long‐term spatial memories along with the inhibition of glucocorticoid receptor‐dependent pathogenic processes and the normalization of plasma glucocorticoid levels. Dazucorilant treatment also resulted in a reduction in tau hyperphosphorylation and amyloid production and aggregation. Additionally, dazucorilant seemed to mediate a specific re‐localization of activated glial cells onto amyloid plaques in J20 mice, suggesting a restoration of physiological neuroinflammatory processes.Conclusion and Implications: Dazucorilant exhibited sustained disease‐modifying effects in two AD models. Given that this compound has demonstrated safety and tolerability in human subjects, our results provide pre‐clinical support for conducting clinical trials to evaluate its potential in AD.
- Open Access
- 26 February 2022
- Published by Elsevier in Neurobiology of Aging
- Vol. 113, 118-130
Sauna-like conditions or menthol treatment reduce tau phosphorylation through mild hyperthermia
- 26 February 2022
- Published by Elsevier in Neurobiology of Aging
- Vol. 113, 118-130
Open AccessSauna-like conditions or menthol treatment reduce tau phosphorylation through mild hyperthermia
- Open Access
- 1 May 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (9) , 2029-2037
Conditional Deletions of Hdc Confirm Roles of Histamine in Anaphylaxis and Circadian Activity but Not in Autoimmune Encephalomyelitis
Histamine is best known for its role in allergies, but it could also be involved in autoimmune diseases such as multiple sclerosis. However, studies using experimental autoimmune encephalomyelitis (EAE), the most widely used animal model for multiple sclerosis, have reported conflicting observations and suggest the implication of a nonclassical source of histamine. In this study, we demonstrate that neutrophils are the main producers of histamine in the spinal cord of EAE mice. To assess the role of histamine by taking into account its different cellular sources, we used CRISPR–Cas9 to generate conditional knockout mice for the histamine-synthesizing enzyme histidine decarboxylase. We found that ubiquitous and cell-specific deletions do not affect the course of EAE. However, neutrophil-specific deletion attenuates hypothermia caused by IgE-mediated anaphylaxis, whereas neuron-specific deletion reduces circadian activity. In summary, this study refutes the role of histamine in EAE, unveils a role for neutrophil-derived histamine in IgE-mediated anaphylaxis, and establishes a new mouse model to re-explore the inflammatory and neurologic roles of histamine.
- 1 May 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (9) , 2029-2037
Open AccessConditional Deletions of Hdc Confirm Roles of Histamine in Anaphylaxis and Circadian Activity but Not in Autoimmune Encephalomyelitis
Histamine is best known for its role in allergies, but it could also be involved in autoimmune diseases such as multiple sclerosis. However, studies using experimental autoimmune encephalomyelitis (EAE), the most widely used animal model for multiple sclerosis, have reported conflicting observations and suggest the implication of a nonclassical source of histamine. In this study, we demonstrate that neutrophils are the main producers of histamine in the spinal cord of EAE mice. To assess the role of histamine by taking into account its different cellular sources, we used CRISPR–Cas9 to generate conditional knockout mice for the histamine-synthesizing enzyme histidine decarboxylase. We found that ubiquitous and cell-specific deletions do not affect the course of EAE. However, neutrophil-specific deletion attenuates hypothermia caused by IgE-mediated anaphylaxis, whereas neuron-specific deletion reduces circadian activity. In summary, this study refutes the role of histamine in EAE, unveils a role for neutrophil-derived histamine in IgE-mediated anaphylaxis, and establishes a new mouse model to re-explore the inflammatory and neurologic roles of histamine.
- 1 January 2010
- Published by Elsevier in EMC - Anesthésie-Réanimation
- Vol. 30 (4) , 1-13
Règles de compatibilité et accidents immunologiques de la transfusion sanguine
- 1 January 2010
- Published by Elsevier in EMC - Anesthésie-Réanimation
- Vol. 30 (4) , 1-13
Règles de compatibilité et accidents immunologiques de la transfusion sanguine